Anthem Biosciences Limited (ANTHEM)

About

Biotech company in healthcare sector, market cap ₹50,148 Cr. Standalone quarterly revenue ₹380–₹610 Cr. Operating margins high at 39.25% (quarterly range 34–46%). Dividend paid June 2026.

Face value: ₹2

Market cap

₹48,213 Cr

P/E

83.7×

P/B

15.8×

Dividend yield

0.2%

ROE

19.5%

ROCE

27.6%

Debt / equity

0.02

OPM

39.3%

EPS (TTM)

₹10.3

Book value

₹54.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE multiple 87.07 elevated; verify earnings growth trajectory and quality justify valuation
Revenue ₹383–₹610 Cr and EPS ₹1.65–₹6.76 volatile across quarters; verify source of volatility and sustainability
FII holding 2.58% (down from 1.28% six months prior) while promoter holds 71.42%; verify barriers to foreign institutional investment or lack of appeal
Biotech-specific: verify pipeline depth, regulatory approval timelines, patent cliffs in core therapies, geographic revenue concentration

Generated analysis · source review pending

Growth drivers

OPM 39.25% (quarterly range 34–46%) high for pharma/biotech; verify whether from pricing power, product mix, or operational efficiency and whether defensible
Debt-to-equity 0.02 provides balance-sheet flexibility for acquisitions or capex expansion; verify management's M&A strategy and growth capex intensity
ROE 19.45% with reinvested earnings compounds growth without external capital dilution; verify R&D spend rate and capex allocation
Standalone revenue ₹550–₹610 Cr in stable recent quarters (Sep–Mar); verify trend direction, therapy/market drivers, and addressable market size

Generated analysis · source review pending

294 historical price candles were omitted because the exchange source has not been verified.

₹855.8-1.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 19.5% (3-yr avg)
+High return on capital employed of 27.6%
+Healthy operating margin of 39.3%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 124.2×
+High promoter holding of 71.4% with no pledge

Cons

−Expensive at 83.7× trailing earnings
−Trading at 15.8× book value
−Promoter holding fell 3.3 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

29/100

Business quality: 86
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 150 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Anthem Biosciences LimitedANTHEMANTHEM	₹48,213 Cr	₹48,264 Cr	₹2,002 Cr	₹793 Cr	39.3%	₹576 Cr	27.9%	27.6%	19.5%	124
Advanced Enzyme Technologies LimitedADVENZYMESADVENZYMES	₹3,072 Cr	₹3,092 Cr	₹750 Cr	₹224 Cr	30.7%	₹166 Cr	23.3%	13.7%	11.1%	331
CCME Global LtdCCMECCME	₹54 Cr	₹54 Cr	₹0 Cr	₹0 Cr	—	₹4 Cr	—	-2.9%	-2.9%	—
Vivo Bio Tech LtdVIVOBIOTVIVOBIOT	₹38 Cr	₹92 Cr	₹47 Cr	₹21 Cr	44%	₹7 Cr	15.6%	15.2%	11%	517
Shree Ganesh Biotech (India) LtdSHREEGANESSHREEGANES	₹19 Cr	₹19 Cr	₹23 Cr	₹-1 Cr	-19.3%	₹0 Cr	7.7%	0.8%	0.6%	846
Genomic Valley Biotech LtdGVBLGVBL	₹9 Cr	₹9 Cr	₹0 Cr	₹-0 Cr	14.8%	₹-1 Cr	11.1%	1%	0.8%	3,565

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2026
Revenue	2,124
COGS	812
Gross profit	1,312
	478
	834
OPM %	39.3%
Depreciation	134
Interest	7
	131
Profit before tax	824
Tax	232
Tax %	28.2%
PAT	592
PAT margin %	27.9%
EPS (₹)	10.6
EPS adjusted (₹)	10.5
	19%
Annual report	Annual report for Mar 2026

₹ Cr	Mar 2026
Equity capital	112
Reserves	2,930
Minority interest	0
	51
	336
Total equity & liabilities	3,429
	781
CWIP	264
Investments	1,010
	1,374
Total assets	3,429

₹ Cr	Mar 2026
	844
	-702
	-40
Net cash flow	103
Free cash flow	633
CFO / Operating profit %	101.3%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 20%

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities
CRDMO	1,772.77	1,132.98	0	0
Speciality Ingredients	351.57	179.07	0	0

SegmentFigure

CRDMO · revenue

₹ crore by fiscal year

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2026
Margins
Gross margin %	61.8%
EBITDA margin %	39.3%
EBIT margin %	32.9%
PAT margin %	27.9%
Working capital
Receivable days	101
Inventory days	56
Payable days	34
NWC days	124
Leverage
Current ratio	5.54
Debt to EBITDA	0.06
Debt to equity	0.02
Interest coverage	124.2
Asset turnover	0.62
Return ratios
Return on assets %	17.3%
Return on capital employed %	27.6%
Return on equity %	19.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.69%	74.69%	74.69%	74.68%	71.42%
	1.5%	1.67%	1.36%	1.28%	2.58%
	3.61%	7.22%	7.6%	11.55%	13.48%
Government	0%	0%	0%	0%	0%
	20.2%	16.42%	16.35%	12.49%	12.52%
No. of shareholders	—	2,17,681	1,99,492	1,80,220	1,73,273

Promoter holding down 3.27 percentage points since Jun 2025.

65 deals · 9 Mar 2026 – 18 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
18 Jun 2026	ARUNA GANESH	Bulk	NSE	Sell	1,71,14,604	₹744.80	₹1,274.70 Cr
18 Jun 2026	ARUNA GANESH	Block	NSE	Sell	1,71,14,604	₹744.80	₹1,274.70 Cr
18 Jun 2026	HDFC MUTUAL FUND	Block	NSE	Buy	13,42,643	₹744.80	₹100.00 Cr
18 Jun 2026	KOTAK MAHINDRA MUTUAL FUND	Block	NSE	Buy	13,42,643	₹744.80	₹100.00 Cr
18 Jun 2026	ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED	Block	NSE	Buy	12,08,379	₹744.80	₹90.00 Cr
18 Jun 2026	BAJAJ LIFE INSURANCE LIMITED	Block	NSE	Buy	12,08,379	₹744.80	₹90.00 Cr
18 Jun 2026	SBI MUTUAL FUND	Block	NSE	Buy	10,78,000	₹744.80	₹80.29 Cr
18 Jun 2026	PRUDENTIAL HONG KONG LIMITED	Block	NSE	Buy	10,20,409	₹744.80	₹76.00 Cr
18 Jun 2026	PI OPPORTUNITIES AIF V LLP	Block	NSE	Buy	8,05,586	₹744.80	₹60.00 Cr
18 Jun 2026	MAHINDRA MANULIFE MUTUAL FUND	Block	NSE	Buy	7,67,411	₹744.80	₹57.16 Cr

1–10 of 65

1 / 7

Mr. AJAY BHARDWAJExecutive Director-Chairperson-CEO-MD
Mr. GANESH SAMBASIVAMExecutive Director
Mr. K RAVINDRA CHANDRAPPAExecutive Director
Mr. RAVIKANT UPPALNon-Executive - Independent Director
Mr. SUBRAMANIAN MADHAVANNon-Executive - Independent Director
Mr. RAMESH RAMADURAINon-Executive - Independent Director
Ms. SHUBHA KULKARNINon-Executive - Independent Director
Mr. SATISH CHANDER SUBBANNANon-Executive - Nominee Director
Mr. Mohammed Gawir BaigChief Financial Officer
Ms. Divya PrasadCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

63

across 13 fund houses

Held by these funds

4.44%

of the company's equity

All mutual funds

11.15%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

63 schemes · 13 fund houses

		Shares
Midcap Fund	SBI Mutual Fund	43.18 L	385.64	1.57%	0.766%	-0
ELSS- Tax Saver Fund	Axis Mutual Fund	29.22 L	260.98	0.8%	0.519%	-0
MNC Fund	SBI Mutual Fund	23.2 L	207.19	3.08%	0.412%	-0
Healthcare Opportunities Fund	SBI Mutual Fund	18.8 L	167.89	2.9%	0.334%	-0
Midcap Fund	Axis Mutual Fund	18.52 L	165.42	0.47%	0.329%	+1.23 L
Portfolio of Kotak Multi Asset Allocation Fund	Kotak Mahindra Mutual Fund	15.79 L	141.02	0.92%	0.28%	-0
PHARMA FUND	Nippon India Mutual Fund	12.75 L	113.87	1.2%	0.226%	+2.17 L
Flexi Cap Fund	Axis Mutual Fund	11.99 L	107.09	0.77%	0.213%	-0

1–8 of 63

1 / 8

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

2

Credit ratings

1

Intimation of Revision in Credit Rating3 Jul 2026

Investor Presentation and earnings call

5

Jul 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Final dividend25 Jun 2026 · ex-date₹2

1

Board meeting to consider results21 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

17 announcementsExport CSV

8 Sept 2026, 10:14 pmCompany Update

Settlement Of Upside Sharing Arrangement

General PDF

27 Jul 2026, 10:52 amCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

24 Jul 2026, 4:06 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

22 Jul 2026, 11:53 pmAGM/EGM

Announcement Under

AGM PDF

22 Jul 2026, 6:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

22 Jul 2026, 11:46 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

21 Jul 2026, 7:25 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

Press Release / Media Release (Revised) PDF

21 Jul 2026, 7:21 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

Date	Category	Subject	Filing
8 Sept 2026, 10:14 pm	Company Update General	Settlement Of Upside Sharing Arrangement	PDF
27 Jul 2026, 10:52 am	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Loading announcements…

Anthem Biosciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

Segment results

CRDMO · revenue

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends1

Board meetings1

Announcements

Dividends1

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

Segment results

CRDMO · revenue

1

1

1

1